Coronavirus disease (COVID-19) is a new respiratory infectious disease caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the family
coronaviridae with wide spreading in humans and animals. This virus is enveloped and
contains positive-sense, single-stranded RNA with approximately 31 kb of genome size and
so far, is considered as the largest known RNA viruses. The COVID-19 infected individuals
exhibit low to modest symptoms (cough, fever, and respiratory distress) and transmitted
mainly by respiratory droplets. However, around 15% of infected individuals proceed to
severe pneumonia and approximately 5% of them progress to acute respiratory distress
syndrome (ARDS), septic shock and/or multiple organ failure. Transmission of SARS-CoV-2
occurs through the means of coughing and sneezing, touching the mouth, nose, eyes, close
personal contact and touching a virus-contaminated object. SARS-CoV-2 disease can induce
both the arms of innate and adaptive immunity, but uncontrolled inflammatory innate
immunity and weakened adaptive immune responses might be associated with destructive
tissue damage, both locally and systemically. Patients with severe COVID-19 exhibited
decrease of lymphocytes, and the elevation of IL-6, IL-10 and C-reactive protein. The
SARS-CoV-2 is a global pandemic threat. Currently, as on August 5, the total number of
COVID-19 cases is approximately 18,354,342 with 696147 deaths were reported worldwide and
216 countries are affected. In India, approximately 1,908,254 individuals were infected
and 39795 deaths occurred due to COVID-19. SARS-CoV-2 disease is often associated with
unconstrained immune response, caused by the hyperactivation of monocytes, macrophages
and elevated neutrophils. Both, humoral (production of IgG, IgM, neutralising antibodies
and reduced memory B cells) and cell mediated (CD4+, CD8+ and cytotoxic markers) immunity
is required for defense against COVID-19. In addition, the activation of Th1 / Th17 cells
might induce the exacerbation of the inflammatory response.

Tuberculosis (TB) is one of the most important infectious diseases around the world.
Tuberculosis (TB), although largely a curable disease, still remains a major cause of
morbidity and mortality worldwide. According to the Global Tuberculosis Report 2019,
there are an estimated 10 million incident cases of tuberculosis and killed 1.2 million
in 2018 globally. India accounts for 27% of all estimated incident cases worldwide. M.
tuberculosis (M.tb) infection could result in the activation of innate (monocytes,
macrophages, dendritic cells, neutrophils, mast cells) and adaptive (CD4+ and CD8+ T
cells, cytotoxic markers) immune response which are necessary for protection. Protective
immunity against M. tuberculosis is not completely understood but depends on a wide range
of innate and adaptive immune mechanisms. T cell-mediated immune responses are important
in the host control of M. tuberculosis infection. The ability of CD4+ T cells to produce
gamma interferon, which activates phagocytes to contain the intracellular pathogen, is
central in protection. Indeed, T helper 1 (Th1) cells and the gamma IFN that they produce
are crucial for protection against disease. This is evident from the increased risk of
tuberculosis in individuals with deficiencies in their IFNγ and interleukin 12 (IL 12;
which promotes Th1 cell differentiation) signalling pathways. Many other CD4+ T cell
subsets, in addition to gamma IFN producing Th1 cells, may also have a role; for example,
IL 17-producing CD4+ T cells were shown to mediate the recruitment of protective Th1
cells to the lung upon M. tuberculosis challenge. Furthermore, increased frequencies of
regulatory CD4+ T regulatory (Treg) cells during active disease may ensure that the Th1
cell response is not excessive, and this would help minimize lung damage in tuberculosis.
The CD8+ T cell response to M. tuberculosis is normally of a lower magnitude than the
CD4+ T cell response; however, CD8+ T cells may modulate phago¬cyte activity or produce
molecules such as granulysin that may be directly cytotoxic to the mycobacteria.
Similarly, other cytokines, in addition to gamma IFN, may also be crucial; for example,
Tumour necrosis factor-alpha is important for establishing the granuloma, which is a
well-organized collection of innate and adaptive cells that forms to contain the
pathogen. Development of TB disease results from interactions among the environment, the
host, and the pathogen, and known risk factors include HIV coinfection, immunodeficiency,
diabetes mellitus, overcrowding, malnutrition, and general poverty.

The link between TB and COVID-19 is likely to be bi-directional. The temporary
immunosuppression induced by tuberculosis may increase the susceptibility of patients to
COVID-19, and COVID may, in turn, also increase susceptibility to TB. In 2025, an
additional 1.4 million TB deaths could be occurred as direct consequence of the COVID-19
pandemic. The COVID-19 disease rate was high in patients with active TB. TB and
SARS-CoV-2 are both infectious diseases which primarily attack the alveolar region of the
lungs and share common symptom patterns. Both CD4 and CD8 counts were severely reduced,
and the surviving T cells appeared to demonstrate "functional exhaustion". This T cell
depletion and dysfunction may exacerbate active TB. Published studies have reported that
patients with TB and other viral infections impede the host immune responses like
induction of type I interferons by influenza infection, lower mean of CD4+ and CD8+ T
cells and increased viral elimination in sputum, stool and suppression of cellular
immunity. Recent studies have reported that cytokines seem to play an important role in
COVID-19 and TB, and their plasma levels associated with disease severity. It is
predicted that people with coinfection have impaired protective immune responses and
treatment outcomes, specifically in terms of anti-tuberculosis treatment. Studies showed
that SARS-CoV2 coexistent with TB resulted in a decreased absolute number of CD4+ and
CD8+ T cells and reduced antibody levels following SARS-CoV-2 recovery. SARS-CoV-2 with
TB patients exhibited prolonged viral elimination from stools and sputum in comparison
without TB. Studies have demonstrated that SARS-CoV-2 disease stimulates increased
cytokine secretion, like interleukin-1 , gamma interferon, tumour necrosis factor- alpha,
interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-10 (IL-10), that ultimately leads
to severe inflammation and their plasma levels were linked with disease severity.
However, only limited information is available on the function of antigen-specific T
cell-mediated immune response to COVID-19 specifically upon coinfection with
tuberculosis, since both the disease primarily affects the lungs.

Limited studies have shown that influenza induces immune system hyperactivity and
exacerbates pulmonary tuberculosis, leading to worsening of pulmonary function.
Respiratory viral infections coexistent with TB delay the host immune responses and lead
to more serious clinical outcomes. Coinfection most probably exacerbates inflammation
through heightened secretion of cytokines and accelerates the development of severe acute
respiratory syndrome and also worsen the TB disease and its outcome. Hence, Investigators
propose that understanding mechanisms of immune regulation during SARS-CoV-2 disease may
lead to the development of better therapeutic strategies and the results of our
fundamental studies may inform future plans for clinical interventional studies. The main
fundamental research component of this study might identify clinical parameters and
treatment methods and to understand the immunological mechanism for the severity in
coinfected SARS-CoV-2 and TB patients.

Hypothesis: Investigators hypothesize that altered immunity due to present or prior
asymptomatic disease with SARS-CoV-2 virus could lead to altered immune responses and
systems biology, increased severity and altered treatment outcomes in TB disease.